RE:RE:RE:RE:RE:It’s time for a turnaround!
I agree with those comments. It seems to me that the kind of detailed analysis being presented, while interesting, is very difficult to impose on an early stage growth company. I think we just need to be assured that we are headed in the right direction, so that we know at some point we will be profitable, and that the growth will continue. Growing revenues is the way to capture that in my view. We went from a price to sales ratio of 20, not long ago, to 5 currently. Not impressive maybe if compared to all other stocks on the TSE, but certainly better than the category of telehealth stocks we are often lumped in with. But the main point is that with growing revenues, especially organic growth, those numbers come down and the price to sales ratio will become lower, 2022 will be our last year of being unprofitable, and then we will be talking about a price/earnings ratio. In the meantime, people, we are scaling our business. This is not Walmart. Its an early stage growth company. Focus on increasing revenues.